Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CCR8 | P51685 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438000 | 0.93 | CYP2D6 (0.47) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5431202 | 0.93 | CYP2D6 (0.49) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5433695 | 0.92 | CYP2D6 (0.59) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5437477 | 0.92 | USP2 (0.47) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5437675 | 0.92 | USP2 (0.50) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5439999 | 0.92 | CCR8 (0.53) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5431123 | 0.91 | CCR8 (0.51) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5434066 | 0.90 | CYP2D6 (0.48) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5434079 | 0.89 | USP2 (0.50) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5437581 | 0.89 | USP2 (0.47) | CYP2D6USP2TSHRSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1678178-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040167-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | CCR8, CCR1, CCR10 | CYP2D6 1764/4885USP2 1826/4885TSHR 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.